DE2521905C2 - Arzneimittel zur cerebralen Durchblutungsförderung - Google Patents
Arzneimittel zur cerebralen DurchblutungsförderungInfo
- Publication number
- DE2521905C2 DE2521905C2 DE2521905A DE2521905A DE2521905C2 DE 2521905 C2 DE2521905 C2 DE 2521905C2 DE 2521905 A DE2521905 A DE 2521905A DE 2521905 A DE2521905 A DE 2521905A DE 2521905 C2 DE2521905 C2 DE 2521905C2
- Authority
- DE
- Germany
- Prior art keywords
- caroverine
- blood flow
- fumarate
- cerebral blood
- medicines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 230000003727 cerebral blood flow Effects 0.000 title claims description 8
- 239000003814 drug Substances 0.000 title description 6
- 229940079593 drug Drugs 0.000 title description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 25
- -1 p-methoxybenzyl Chemical group 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 2
- 229940126601 medicinal product Drugs 0.000 claims 1
- MSPRUJDUTKRMLM-UHFFFAOYSA-N caroverine Chemical compound O=C1N(CCN(CC)CC)C2=CC=CC=C2N=C1CC1=CC=C(OC)C=C1 MSPRUJDUTKRMLM-UHFFFAOYSA-N 0.000 description 26
- 229960003355 caroverine Drugs 0.000 description 24
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 21
- 239000000126 substance Substances 0.000 description 11
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 8
- 210000004004 carotid artery internal Anatomy 0.000 description 8
- 210000002385 vertebral artery Anatomy 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 210000001367 artery Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 5
- FYJJXENSONZJRG-UHFFFAOYSA-N bencyclane Chemical compound C=1C=CC=CC=1CC1(OCCCN(C)C)CCCCCC1 FYJJXENSONZJRG-UHFFFAOYSA-N 0.000 description 5
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 5
- 229960000876 cinnarizine Drugs 0.000 description 5
- 229960001789 papaverine Drugs 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 238000009519 pharmacological trial Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000005956 quaternization reaction Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH695774A CH592637A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1974-05-21 | 1974-05-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2521905A1 DE2521905A1 (de) | 1975-12-04 |
| DE2521905C2 true DE2521905C2 (de) | 1986-06-26 |
Family
ID=4317694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2521905A Expired DE2521905C2 (de) | 1974-05-21 | 1975-05-16 | Arzneimittel zur cerebralen Durchblutungsförderung |
Country Status (13)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0032564A1 (de) * | 1979-12-28 | 1981-07-29 | Medichemie Ag | Pharmazeutische Verwendung von Caroverin und/oder Caroverinsalzen sowie Caroverinsalze mit Xanthinderivat-Säureresten und Nicotinsäurerest |
| JPS6115033U (ja) * | 1984-07-04 | 1986-01-28 | 石川島播磨重工業株式会社 | 圧力容器内のガス抜き装置 |
| AT408837B (de) * | 1998-06-19 | 2002-03-25 | Phafag Ag | Verwendung von caroverin und/oder caroverin. hydrochlorid zur herstellung von als antioxidantien wirkenden zusammensetzungen und/oder von neuroregenerativen zusammensetzungen |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1189552B (de) * | 1959-07-03 | 1965-03-25 | Donau Pharmazie Ges M B H | Verfahren zur Herstellung von 2-Oxo-1, 2-dihydrochinoxalinen und von deren Salzen und quaternaeren Ammoniumverbindungen |
| CH513884A (de) * | 1967-10-23 | 1971-10-15 | Donau Pharmazie Gmbh | Verfahren zur Herstellung von Tetrahydro-Chinoxalin-2-onen |
-
1974
- 1974-05-21 CH CH695774A patent/CH592637A5/xx not_active IP Right Cessation
-
1975
- 1975-05-06 GB GB1887475A patent/GB1461558A/en not_active Expired
- 1975-05-13 FR FR7514844A patent/FR2272087B1/fr not_active Expired
- 1975-05-14 SE SE7505555A patent/SE414634B/xx unknown
- 1975-05-14 AU AU81144/75A patent/AU8114475A/en not_active Expired
- 1975-05-14 AT AT368375A patent/AT342059B/de not_active IP Right Cessation
- 1975-05-14 BE BE156363A patent/BE829085A/xx not_active IP Right Cessation
- 1975-05-14 CA CA226,964A patent/CA1037477A/en not_active Expired
- 1975-05-15 NL NL7505715A patent/NL7505715A/xx not_active Application Discontinuation
- 1975-05-16 DE DE2521905A patent/DE2521905C2/de not_active Expired
- 1975-05-19 ES ES437774A patent/ES437774A1/es not_active Expired
- 1975-05-20 DK DK220675AA patent/DK138420B/da not_active IP Right Cessation
- 1975-05-20 JP JP6009775A patent/JPS5642599B2/ja not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| AT342059B (de) | 1978-03-10 |
| CA1037477A (en) | 1978-08-29 |
| AU8114475A (en) | 1976-11-18 |
| DK138420B (da) | 1978-09-04 |
| ATA368375A (de) | 1977-07-15 |
| SE414634B (sv) | 1980-08-11 |
| SE7505555L (sv) | 1975-11-24 |
| FR2272087B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1979-06-22 |
| JPS50160417A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1975-12-25 |
| NL7505715A (nl) | 1975-11-25 |
| ES437774A1 (es) | 1977-01-16 |
| DK220675A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1975-11-22 |
| JPS5642599B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1981-10-06 |
| DE2521905A1 (de) | 1975-12-04 |
| DK138420C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1978-09-04 |
| FR2272087A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1975-12-19 |
| GB1461558A (en) | 1977-01-13 |
| BE829085A (fr) | 1975-09-01 |
| CH592637A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1977-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE1792711C3 (de) | Verwendung von Alkanolaminderivaten | |
| DE1670827C3 (de) | 4-(2'-Nitrophenyl)-2,6-dimethyl-3,5-dicarbmethoxy-1,4-dihydropyridin | |
| DE3019350C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| EP0185210B1 (de) | Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Behandlung von an amyotropher Lateralsklerose Erkrankten | |
| EP0188810A2 (de) | Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Verhinderung oder Behandlung posttraumatischer Nervenschäden nach unfallbedingten Rückenmarks- und/oder Gehirntraumen | |
| DE2414273C3 (de) | N-Methyl-D-glucaminsalz von 2-(2'-Methyl-3'-trifluormethyl-anilin)-nicotinsäure, Verfahren zu seiner Herstellung und es enthaltende Arzneimittelzubereitung | |
| DE3000743C2 (de) | Arzneipräparat auf der Basis eines Salzes der Acetylsalicylsäure und einer basischen Aminosäure | |
| DE2166355C2 (de) | Verwendung von d,1-Sobrerol bei der Balsamtherapie der Atemwege | |
| DE2716402A1 (de) | 7-(2,3-dihydroxypropyl)-1,3-di-n- propylxanthin, verfahren zu seiner herstellung und diese verbindung enthaltende arzneimittel | |
| DE2521905C2 (de) | Arzneimittel zur cerebralen Durchblutungsförderung | |
| DE2123318C2 (de) | 4-Butylamino-1-äthyl-1H-pyrazolo[3,4-b]pyridin-5-carbonsäureäthylester, Verfahren zu dessen Herstellung und diesen enthaltende pharmazeutische Mittel | |
| EP0114048B1 (de) | Verwendung von D,L- und D-Carazolol zur Herstellung von Antiglaukommitteln sowie Arzneimittel, die D-Carazolol enthalten | |
| DE2609746A1 (de) | Piperazinverbindungen sowie arzneimittel, die diese verbindungen enthalten | |
| DE1900772C3 (de) | Salz aus N,N-Dimethylbiguanid und p-Chlorphenoxyessigsäure sowie dieses enthaltende Arzneimittel | |
| DE2038628C3 (de) | N,N'-Di(carboxyalkyI)-p-phenylendiamine, deren Salze und Diäthylester, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| DE2242787C2 (de) | 4-Phenyl-6-amino-3,4-dihydropyridon-(2)-3,5-dicarbonsäure-diäthylesterderivate, ein Verfahren zu deren Herstellung und diese enthaltende Arzneimittel | |
| DE3689254T2 (de) | Arzneimittel auf Dextrorphanbasis zur intranasalen Applikation. | |
| DE2148986C3 (de) | Salze der Chondroitinschwefelsäure mit Carboxymethyl-trhnethylammoniumhydroxid, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| CH634302A5 (de) | Verfahren zur herstellung neuer mercaptomethylpyridin-derivate. | |
| DE2724608C2 (de) | 1-(4-Isopropylthiophenyl)-2-n-octylaminopropanol enthaltende pharmazeutische Zubereitung | |
| DE2416339B2 (de) | Argininpyroglutamat, Verfahren zu seiner Herstellung und Arzneimittel | |
| DE3887426T2 (de) | Eperisone als Hypotonikum. | |
| DE2749075C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE1792764A1 (de) | Kreislaufbeeinflussende mittel | |
| DD283931A5 (de) | Verfahren zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von herzrhythmusstoerungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OD | Request for examination | ||
| 8128 | New person/name/address of the agent |
Representative=s name: JUNG, E., DIPL.-CHEM. DR.PHIL. SCHIRDEWAHN, J., DI |
|
| 8125 | Change of the main classification |
Ipc: A61K 31/495 |
|
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |